HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaluski, E. Search for Related Content PubMed PubMed Citation Articles by Kaluski, E.

RITZ-5: randomized intravenousTeZosentan (an endothelin-A/B antagonist)for the treatment of pulmonary edema

A prospective, multicenter, double-blind, placebo-controlled study

Edo Kaluski, MD, FACC^*,*, Isaac Kobrin, MD^||, Reuven Zimlichman, MD, Alon Marmor, MD, Oscar Krakov, MD, Olga Milo, MD^*, Aline Frey, PharmD^||, Shoshana Kaplan, MD^*, Rikardo Krakover, MD^*, Avi Caspi, MD^||, Zvi Vered, MD, FACC^*, Gad Cotter, MD^* RITZ-5 Investigators

^* Cardiology Division, Assaf-Harofeh Medical Center, Zerifin, Israel
Department of Medicine-Edith Wolfson Medical Center, Holon, Israel
Cardiology Department–Rivka Ziv Medical Center, Safad, Israel
Cardiology Division–Kaplan Medical Center, Rehovot, Israel
^|| Actelion Ltd., Allschwil, Switzerland

View larger version (25K): [in a new window]   Figure 1 (A) Mean arterial blood pressure (MAP) decrease during the first 90 min of treatment: tezosentan versus placebo. Filled diamonds = tezosentan (n = 42); filled squares = placebo (n = 42). (B) Systolic blood pressure (SBP) decrease during the first 90 min of treatment: tezosentan versus placebo. BL = baseline.

View larger version (19K): [in a new window]   Figure 2 Time to death, cardiac failure, pulmonary edema, or cardiogenic shock. Patients were treated by placebo or 50 and 100 mg/h of tezosentan.